Prospective randomized phase IV open label comparative study of dalteparin vs unfractionated heparin in high risk patients of non-ST elevation acute coronary syndromes intended for early invasive strategy.

Trial Profile

Prospective randomized phase IV open label comparative study of dalteparin vs unfractionated heparin in high risk patients of non-ST elevation acute coronary syndromes intended for early invasive strategy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2011

At a glance

  • Drugs Dalteparin sodium; Heparin
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Oct 2011 Actual initiation date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top